Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell

The analysis of genomic distribution of retroviral vectors is a powerful tool to monitor ‘vector‐on‐host’ effects in gene therapy (GT) trials but also provides crucial information about ‘host‐on‐vector’ influences based on the target cell genetic and epigenetic state. We had the unique occasion to compare the insertional profile of the same therapeutic moloney murine leukemia virus (MLV) vector in the context of the adenosine deaminase‐severe combined immunodeficiency (ADA‐SCID) genetic background in two GT trials based on infusions of transduced mature lymphocytes (peripheral blood lymphocytes, PBL) or a single infusion of haematopoietic stem/progenitor cells (HSC). We found that vector insertions are cell‐specific according to the differential expression profile of target cells, favouring, in PBL‐GT, genes involved in immune system and T‐cell functions/pathways as well as T‐cell DNase hypersensitive sites, differently from HSC‐GT. Chromatin conformations and histone modifications influenced integration preferences but we discovered that only H3K27me3 was cell‐specifically disfavoured, thus representing a key epigenetic determinant of cell‐type dependent insertion distribution. Our study shows that MLV vector insertional profile is cell‐specific according to the genetic/chromatin state of the target cell both in vitro and in vivo in patients several years after GT.

[1]  L. Notarangelo,et al.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.

[2]  Hanno Glimm,et al.  High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.

[3]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[4]  Zhixiong Li,et al.  Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  F. Bushman.  Retroviral integration and human gene therapy. , 2007, The Journal of clinical investigation.

[6]  F. Bushman,et al.  HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. , 2007, Genome research.

[7]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[8]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[9]  M. Roncarolo,et al.  Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. , 2008, Blood.

[10]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[11]  M. Hansmann,et al.  Resistance of mature T cells to oncogene transformation. , 2008, Blood.

[12]  Paul Shinn,et al.  Retroviral DNA Integration: Viral and Cellular Determinants of Target-Site Selection , 2006, PLoS pathogens.

[13]  D. Kohn,et al.  Gene therapy fulfilling its promise. , 2009, The New England journal of medicine.

[14]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[15]  C. Di Serio,et al.  Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. , 2009, Blood.

[16]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[17]  Yuka Kanno,et al.  Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. , 2009, Immunity.

[18]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[19]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[20]  A. Schambach,et al.  Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Nirav Malani,et al.  HIV integration site distributions in resting and activated CD4+ T cells infected in culture , 2009, AIDS.

[22]  A. Ciuffi.  Mechanisms governing lentivirus integration site selection. , 2008, Current gene therapy.

[23]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[24]  Z. Weng,et al.  High-Resolution Mapping and Characterization of Open Chromatin across the Genome , 2008, Cell.

[25]  Frederic D. Bushman,et al.  Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. , 2010, Blood.

[26]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[27]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[28]  C. Shaw,et al.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. , 2007, Blood.

[29]  Jane M J Lin,et al.  Identification and Characterization of Cell Type–Specific and Ubiquitous Chromatin Regulatory Structures in the Human Genome , 2007, PLoS genetics.

[30]  L. Naldini.  A Comeback for Gene Therapy , 2009, Science.

[31]  Luca Biasco,et al.  Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.

[32]  M. Cavazzana‐Calvo,et al.  Lymphoid-affiliated genes are associated with active histone modifications in human hematopoietic stem cells. , 2008, Blood.

[33]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[34]  Frederic D Bushman,et al.  Massively parallel pyrosequencing in HIV research. , 2008, AIDS.

[35]  Dustin E. Schones,et al.  Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. , 2009, Cell stem cell.

[36]  C. Bordignon,et al.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[38]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[39]  Alessandro Aiuti,et al.  Hot spots of retroviral integration in human CD34+ hematopoietic cells. , 2007, Blood.

[40]  Davide Cittaro,et al.  Transcription Factor Binding Sites Are Genetic Determinants of Retroviral Integration in the Human Genome , 2009, PloS one.